EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale

Zahinoor Ismail, Stine R Meehan, Anja Farovik, Maia Miguelez, Shivani Kapadia, Stephane Alexandre Regnier, Zhen Zhang, T Michelle Brown, Mirline Milien, Roger S McIntyre

Schizophrenia Research · 2024

DOI: 10.1016/j.schres.2024.10.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Schizophrenia Research, 2024. Verfasst von Zahinoor Ismail und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Psychiatry, Clinical Neurosciences, and Community Health Sciences, Hotchkiss Brain Institute and O'Brien Institute for Public Health, …. Hauptthemen laut MEDLINE: Schizophrenia, Psychiatric Status Rating Scales. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, National Natural Science Foundation of China, Otsuka Pharmaceutical Development and Commercialization Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Improved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research aimed to determine whether certain items from the Positive and Negative Syndrome Scale (PANSS) can assess patient life engagement in schizophrenia. METHODS: Three approaches were used to identify PANSS items that reflect patient life engagement: (1) a panel discussion with expert psychiatrists (n = 4); (2) interviews with patients with schizophrenia (n = 20); and (3) a principal component analysis to explore clustering of items (n = 954 from three randomized controlled trials). Internal consistency was assessed by Cronbach's alpha and item-total correlations. A minimal clinically important difference (MCID) was determined by anchor- and distribution-based methods. RESULTS: Expert psychiatrists identified 11 relevant items, and patients rated 13 items as "very relevant" to patient life engagement, most of which clustered in the principal component analysis. Considering all results, a composite set of 14 PANSS items that may be relevant to patient life engagement in schizophrenia was devised: P2, N1, N2, N3, N4, N5, N6, N7, G6, G7, G11, G13, G15, G16 (Cronbach's alpha, 0.84; item-total correlations, 0.35-0.56, indicating acceptable correlation with the underlying concept; exception: G6 [depression], 0.19). An MCID of 5 points (small/moderate improvement) or 10 points (large improvement) may be appropriate. CONCLUSIONS: A subset of 14 PANSS items may be used to reflect patient life engagement in clinical practice/trials in schizophrenia, complementing the results of traditional psychiatric symptom scales with a patient-centered outcome that is relevant to real-world treatment goals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaPsychiatric Status Rating ScalesHumansMaleFemaleAdultMiddle AgedSchizophrenic PsychologyPrincipal Component AnalysisPatient ParticipationMinimal Clinically Important Difference

Stichwörter der Autor:innen

Life engagementMinimal clinically important differencePatient interviewPsychometricsSchizophrenia

Autor:innen und Institutionen

  • Departments of Psychiatry, Clinical Neurosciences, and Community Health Sciences, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada; Clinical and Biomedical Sc…
  • Global Medical Affairs, H. Lundbeck A/S, Valby, Denmark.
  • Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.
  • Value Evidence Analytics and HEOR, H. Lundbeck A/S, Valby, Denmark.
  • Medical and Real-World Data Analytics, Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.
  • RTI Health Solutions, Research Triangle Park, NC, USA.

Förderung

  • Canadian Institutes of Health Research
  • National Natural Science Foundation of China
  • Otsuka Pharmaceutical Development and Commercialization Inc
  • Global Alliance for Chronic Diseases
  • Fondation Brain Canada
  • National Institute for Health and Care Research
  • National Institutes of Health
  • Milken Institute

Zitieren

APA

Ismail, Z., Meehan, S. R., Farovik, A., Miguelez, M., Kapadia, S., Regnier, S. A., Zhang, Z., Brown, T. M., Milien, M., & McIntyre, R. S. (2024). Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale. Schizophrenia Research. https://doi.org/10.1016/j.schres.2024.10.008

Vancouver

Ismail Z, Meehan SR, Farovik A, Miguelez M, Kapadia S, Regnier SA, et al. Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale. Schizophrenia Research. 2024. doi:10.1016/j.schres.2024.10.008

BibTeX
@article{Ismail2024,
  author = {Ismail, Zahinoor and Meehan, Stine R and Farovik, Anja and Miguelez, Maia and Kapadia, Shivani and Regnier, Stephane Alexandre and Zhang, Zhen and Brown, T Michelle and Milien, Mirline and McIntyre, Roger S},
  title = {Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale},
  journal = {Schizophrenia Research},
  year = {2024},
  doi = {10.1016/j.schres.2024.10.008}
}
Kostenlos starten →